Raymond James restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report sent to investors on Monday, MarketBeat Ratings reports. Raymond James currently has a $40.00 target price on the stock, down from their prior target price of $75.00. IRON has been the subject of several other reports. […]
Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective decreased by research analysts at Stifel Nicolaus from $104.00 to $71.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 107.54% from the stock’s […]
Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective cut by Morgan Stanley from $75.00 to $40.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 26.78% from the stock’s previous close. A […]
Disc Medicine, Inc. (NASDAQ:IRON – Free Report) – Investment analysts at Leerink Partnrs reduced their Q1 2024 EPS estimates for shares of Disc Medicine in a note issued to investors on Thursday, March 21st. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($1.10) per share for the quarter, down from their […]
Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has received a consensus recommendation of “Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. […]